Table 1.

A summary of the demographic, pharmacological and CNS related data (mean ± SEM) for the 15 donors with schizophrenia and 15 controls used in this study

	Age (yr)	Gender (M/F)	PMI (h)	pH	DI	FRADD	LEAP
Controls	60 ± 3.9	7/8	44 ± 4.2	6.30 ± 0.07
Schizophrenia	59 ± 3.0	7/8	44 ± 2.9	6.33 ± 0.05	29 ± 2.9	379 ± 74	1110 ± 272
p	0.92	1.00	0.87	0.64

DI duration of illness, F female, FRADD final recorded antipsychotic drug dose expressed as chlorpromazine equivalents per day, LEAP lifetime exposure to antipsychotic drugs expressed as chlorpromazine equivalents/10,000, PMI postmortem interval, M male, yr year